The effectiveness of complex therapy in patients with gout using carbon enterosorbent
Keywordsgout, non-alcoholic fatty liver disease, treatment, enterosorbent.
Introduction. Gout is a serious medical, social and economic problem today. It becomes even more important due to its comorbidity. The relationship of pathogenetic mechanisms in the development and progression of gout and non-alcoholic fatty liver disease (NAFLD) has been proven. The presence of concomitant pathology enhances the inflammatory reaction in the body and significantly complicates the course of the underlying disease.
The aim of the study – to evaluate the indicators of systemic inflammatory response in patients with gout and gout with NAFLD when included in the complex therapy of the disease carbon enterosorbent carboline.
Materials and Methods. 123 patients with gout in the period of exacerbation were examined, who were divided into two groups. Group I included 65 patients with gout without liver damage, group II – 58 people with concomitant NAFLD. To determine the effectiveness of treatment, both groups were divided into subgroups: IA (27 people) and IIA (23 patients) who received conventional treatment. Subgroups IB (38 patients) and IIB (35 subjects) additionally received enterosorbent carboline. The control group consisted of 30 healthy individuals. A general clinical examination (collection of complaints, history, objective examination), determination of pain intensity on a visual-analog scale (VAS), biochemical (uric acid level (UA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) ) and enzyme-linked immunosorbent assays (tumor necrosis factor-α) (TNF-α), interleukins 1 (IL-1β) and 10 (IL-10) were conducted.
Results. Patients in both groups had typical clinical signs of joint syndrome. In patients with gout an increase in UA, CRP, ESR, imbalance of cytokine regulation (IL-1β, TNF-α, IL-10) was revealed. These changes increased in the presence of concomitant NAFLD. Significant decrease in the concentration of UA, CRP, ESR, cytokine content after treatment was in all subgroups, but more in patients who received carbon enterosorbent with basic therapy.
Conclusions. The inclusion of the carbon enterosorbent carboline in the complex treatment of patients with gout and gout with NAFLD in the acute phase, promotes faster reverse dynamics of the clinical manifestations of the disease, accompanied by a more significant decrease of the level of UA, CRP, ESR and cytokines in blood serum.
Palla I, Fusco F, Tani C, Baldini C, Mosca M, Turchetti G. The economic impact of gout: a systematic literature review. Clin Exp Rheumatol. 2012;30(73): S145-S148.
Edwards NL, Sundy JS, Forsythe A, Blume S,. Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10-15, DOI: 10.3111/13696998.2010.540874.
Ragab G, Elshahaly M, Bardin TJ. Gout: An old disease in new perspective: a review. Adv Res. 2017;8(5):495–511.
Cavalcanti NG, Marques CDL, Lins e Lins TU, Pereira MC, Rêgo M JBDM, Duarte ALBP, et al. Cytokine profile in gout: inflammation driven by IL-6 and IL-18? Immunological investigations. 2016:45(5);383-395. DOI: 10.3109/08820139.2016.1153651 PMID: 27219123.
Barskova VG, Eliseev MS, Denisov IS, Eliseeva ME, Belikov OA, Fadienko GR, i dr. Chastota metabolicheskogo sindroma i soputstvuiushchikh zabolevanii u bolnykh podagroi. Dannye mnogotcentrovogo issledovaniia [The frequency of metabolic syndrome and concomitant diseases in patients with gout. Data from a multicenter study]. Nauchno-prakticheskaia revmatologiia. 2012;6(50):15-18. Russian.
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1): 123. doi:10.1186/s12916-017-0890-9.
Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA internal medicine. 2017;177(5):633–640.
Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J. Hepatol. 2019;70(3):531-44. PMID:30414863 doi: 10.1016/j.jhep.2018.10.033.
Shih MH, Lazo M, Liu SH, Bonekamp S, Hernaez R, Clark JM.. Association between serum uric acid and nonalcoholic fatty liver disease in the US population. Journal of the Formosan Medical Association. 2015;114(4): 314-320.
Clinical practice guidelines for the management of non-alcoholic fatty liver disease European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9(2):65–90. doi:10.1159/000443344.
Maltsev DV, Natrus LV, Kondratiuk VYe, Degtyarova IE. Immunological aspects of pathogenesis of gout in light of recent scientic discoveries as a key for development of informative biomarkers and innovative therapeutic strategies. Biol. Stud. 2018: 12 (3–4); 103–116. DOI: 10.30970/sbi.1203.572.
Hyndman D, Liu S, Miner JN. Urate handling in the human body. Current rheumatology reports. 2016;18(6):34. DOI: 10.1007/s11926-016-0587-7
Xu X, Li C, Zhou P, Jiang T. Uric acid transporters hiding in the intestine. Pharmaceutical biology. 2016;54(12):3151-5.
Abrahamovych OO, Faiura OP, Abrahamovych UO. Komorbidnist: suchasnyi pohliad na problemu; klacyfikatsiia (povidomlennia druhe) [Comorbidity: a modern perspective on the problem; classification (message second)]. Lviv Clinical Bulletin. 2016;1:31-9. Ukrainian.
Smiian SI, Danchak SV. Otsinka kardiovaskuliarnoho ryzyku u patsiientiv iz podahroiu ta nealkoholnoiu zhyrovoiu khvoroboiu pechinky [Cardiovascular risk assessment in patients with gout and nonalcoholic fatty liver disease]. Patolohiia. 2015; 3(35):36-40. Ukrainian.
Levenets LS. Enterosorbtsiia yak metod eferentnoi terapii. Zahalna kharakterystyka ta vydy sorbentiv [Enterosorption as a method of efferent therapy. General characteristics and types of sorbents]. Aktualni problemy klinichnoi ta profilaktychnoi medytsyny. 2016;4 (1):22-8. Ukrainian.
Lototska SV. Obgruntuvannia vykorystannia enterosorbeniv u likuvanni syndromu endohennoi intoksykatsii pry riznomanitnykh zakhvoriuvanniakh (ohliad literatury) [Rationale for the use of enterosorbents in the treatment of endogenous intoxication syndrome in various diseases (literature review)]. Bukovynskyi medychnyi visnyk. 2015;19(1): 222-226. Ukrainian.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 199
Number of citations: 0